AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
X4 Pharmaceuticals, Inc. Common Stock
XNAS · usd
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG001TCY1B7
3.24▲ 0.04 (1.25%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
3.20
Day's Range
3.02 – 3.25
52-Week Range
2.43 – 4.83
Volume
533.6K
Avg Volume
904.3K
Share Statistics
Shares Outstanding
Employees
45
Exchange
XNAS
Listed
2017-11-16
Share count as of July 31, 2026

X4 Pharmaceuticals, Inc. Common Stock (XFOR) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about X4 Pharmaceuticals, Inc. Common Stock (XFOR)
What is X4 Pharmaceuticals, Inc. Common Stock's Market Cap?
X4 Pharmaceuticals, Inc. Common Stock's Market Cap is $321.2M, based on as-reported figures from SEC (XBRL) filings.
What is X4 Pharmaceuticals, Inc. Common Stock's Enterprise Value?
X4 Pharmaceuticals, Inc. Common Stock's Enterprise Value is $201.1M, based on as-reported figures from SEC (XBRL) filings.
What is X4 Pharmaceuticals, Inc. Common Stock's Price / Sales?
X4 Pharmaceuticals, Inc. Common Stock's Price / Sales is 20.3×, based on as-reported figures from SEC (XBRL) filings.
What is X4 Pharmaceuticals, Inc. Common Stock's EV / Revenue?
X4 Pharmaceuticals, Inc. Common Stock's EV / Revenue is 12.7×, based on as-reported figures from SEC (XBRL) filings.
What is X4 Pharmaceuticals, Inc. Common Stock's EV / EBITDA?
X4 Pharmaceuticals, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is X4 Pharmaceuticals, Inc. Common Stock's Revenue (TTM)?
X4 Pharmaceuticals, Inc. Common Stock's Revenue (TTM) is $15.8M, based on as-reported figures from SEC (XBRL) filings.
What is X4 Pharmaceuticals, Inc. Common Stock's Net Income (TTM)?
X4 Pharmaceuticals, Inc. Common Stock's Net Income (TTM) is -$90.1M, based on as-reported figures from SEC (XBRL) filings.
What is X4 Pharmaceuticals, Inc. Common Stock's EBITDA?
X4 Pharmaceuticals, Inc. Common Stock's EBITDA is -$86.2M, based on as-reported figures from SEC (XBRL) filings.
What is X4 Pharmaceuticals, Inc. Common Stock's Diluted EPS (TTM)?
X4 Pharmaceuticals, Inc. Common Stock's Diluted EPS (TTM) is -0.91, based on as-reported figures from SEC (XBRL) filings.
What is X4 Pharmaceuticals, Inc. Common Stock's EBITDA Margin?
X4 Pharmaceuticals, Inc. Common Stock's EBITDA Margin is -544.2%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · XFORAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Numerator:
Total revenue
YoY growth-69.4%+79.1%+215.2%
Costs and operating expenses:
Cost of revenue
Research and development
General and administrative
Total operating expense
Loss from operations
% of revenue-186.1%-922.9%-1558.6%
Other income, net:
Interest income
Interest expense
Change in fair value of warrant liability
Other income, net
Total other income, net
Loss before provision for income taxes
Provision for income taxes
Net loss
% of revenue-183.5%-931.7%-1689.2%
Net loss per share attributable to common stockholders—basic—
Net loss per share attributable to common stockholders—diluted—